Asia Pacific Narcolepsy Drugs Market Research Report – Segmented By Type, Indication and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 6663
Pages: 142

APAC Narcolepsy Drugs Market Size (2023 to 2028)

The size of the Narcolepsy Drugs Market in the Asia Pacific is forecasted to hike at a healthy CAGR from 2023 to 2028.

The active participation of healthcare facilities to raise awareness of the disorder and its symptoms is driving the growth of the narcolepsy drugs market in the APAC region. Other factors, such as growing concern about the benefits of early diagnosis of narcolepsy, coupled with government efforts to educate individuals and trained professionals about the disease, are accelerating market growth.  Neurological disorders related to sleep are an emerging problem as the population ages at a rapid rate. The most common diagnoses other than narcolepsy were sleep apnea syndrome and sleep-wake schedule disorder in China. The prevalence rate of narcolepsy in southern China was recorded to be 0.035%. Extreme drowsiness affects most people, and sleep disturbances increase the risk associated with symptoms. In addition, cataplexy is expected to develop at a higher rate due to the sudden loss of muscle control by patients with cataplexy.

Narcolepsy without cataplexy will lead the narcolepsy drugs market in APAC during the prognostic period, owing to improving awareness of excessive daytime sleepiness with or with REM sleep patterns. Several organizations are focusing on spreading knowledge about the various sleep disorders, and their treatment options are leading to an increase in narcolepsy awareness programs. However, due to the low awareness and inaccurate depictions of the disease, most people with narcolepsy are undiagnosed. Without the diagnosis and care of a sleep specialist, the symptoms of narcolepsy can be misinterpreted as laziness or a character defect. They can limit educational and employment opportunities or lead to misdiagnosis. Additionally, the substantial portfolio of drugs for the treatment of narcolepsy is expected to positively impact the growth of the APAC narcolepsy market in the coming years. The spectrum of drugs involving sodium oxybate will increase the company portfolio.

However, the side effects and risks associated with ant narcoleptic drugs, primarily due to sodium oxybate causing central nervous system depressant, respiratory depression, seizures, and their potential for abuse. Another factor that will challenge the market can be late diagnosis and misdiagnosis of narcolepsy with other sleep disorders.

This research report on the APAC narcolepsy drugs market has been segmented and sub-segmented into the following categories.

By Type:

  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Sodium Oxybate
  • Selective Serotonin Reuptake Inhibitor
  • Others

By Indication:

  • Daytime Extreme Sleepiness
  • Cataplexia
  • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

In 2020, the regional market in Australia dominated the studied market. It is forecasted to continue to be the largest share in the APAC market during the forecast period due to increased healthcare spending in this region, significant sedentary lifestyle changes, and growing awareness in the population about various sleep disorders. According to data from the journal Sleep Science in 2018, approximately 1 in 2,000 people are suffering from narcolepsy across the globe. Moreover, the Australian Institute of Health and Welfare stated that around two-thirds, i.e., 64% of the Australian population aged 18 years and more, are estimated to be overweight or obese and have higher chances of contracting the disorder.

It is estimated that the APAC regions like India, Singapore, Malaysia, and South Korea are anticipated to have lucrative growth due to higher prevalence in Japan and the presence of emerging economies, increased research and development initiatives to advance new drugs against narcolepsy. With recent improvements in knowledge about narcolepsy, drugs targeting hypocretin have been developed, with no permanent cure and only symptomatic relief.

The Chinese market is predicted to grow due to the increasing prevalence of unhealthy lifestyles, better reimbursement policies, and technological advancements for disease diagnosis. Moreover, the growing number of cases of narcolepsy leading to increased awareness of treatment and increased healthcare expenditure is driving the growth of the market.


Companies playing a leading role in the Asia Pacific Narcolepsy Drugs Market analyzed in this report are Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample